Advocacy & Awareness

Advocacy Events & Calls to Action

Voice of the Patient Report

On May 1, 2024, the beginning of PWS Awareness Month, we announced the release of the Voice of the Patient Report. This timely filing marks a significant moment for the Prader-Willi syndrome community! The report gives crucial insights that amplify the perspective of individuals and families affected by PWS and sheds light on aspects of PWS that may not be fully captured in drug trials alone. Integrating the patient’s voice throughout the drug approval process for PWS treatments is essential for the U.S. Food and Drug Administration’s (FDA) comprehensive understanding and impactful decision-making. 

The Voice of the Patient Report was created following the June 2023 PWS Externally-Led Patient-Focused Drug Development (EL-PFDD) Meeting and is compiled of testimonials shared during the EL-PFDD meeting, as well as those submitted virtually.

PWSA | USA, FPWR, and IPWSO extend heartfelt gratitude to the entire PWS community for contributing to the success of this project. To truly amplify the patient’s voice, our entire community must commit to ongoing advocacy efforts. This entails incorporating patient perspectives into all facets of processes and systems, ensuring genuine and enduring change. It’s not solely about isolated advocacy initiatives—it’s about steadfast dedication to embracing and elevating the voices of those directly affected by Prader-Willi syndrome.

You can read the Voice of the Patient Report by clicking the button below.

Find your Representative

PWS State Qualifier Campaign

We are excited to share that several new community members are in the beginning stages of having PWS added to their state’s list of developmental disabilities.

PWS State Qualifier Campaign Map

If you or someone you know is interested in leading the charge in your state, please email PWSA | USA at Advocacy@pwsausa.org.

Meet some of PWSA | USA’s advocates

PWSA | USA's Advocacy in Action Webinar

Check Out PWSA | USA'S
PWS Awareness Month Hub

A Big Step Forward
EL-PFDD Meeting

Your voice made a difference! PWS’s First Externally Led Patient-Focused Drug Development Meeting was a success. We have officially filed the Voice of the Patient Report, which is a document put together to include the stories shared during the meeting and submitted virtually. Click the button below to find the report and to learn more about the EL-PFDD.

VISIT OUR BLOG

FDA Responds to PWS Advocacy Coalition’s Petition on DCCR

FDA Responds to PWS Advocacy Coalition’s Petition on DCCR

PWSA | USA is excited to share an update on the continuous advocacy efforts for the PWS community. We have received a letter from the U.S. Food and Drug Administration (FDA) in response to a petition submitted by the PWS Advocacy Coalition (submitted on July 31, 2024). This petition urged the FDA to prioritize the […]

FDA Advisory Committee to Review DCCR as Treatment for Hyperphagia in PWS

FDA Advisory Committee to Review DCCR as Treatment for Hyperphagia in PWS

The FDA has announced its plan to conduct an Advisory Committee Meeting as part of its review of Soleno Therapeutics’ DCCR New Drug Application. The FDA convenes Advisory Committees to provide independent expert advice that contributes to the agency’s regulatory decision-making. As part of the Advisory Committee Meeting, interested community members are encouraged to share […]

PWS Advocacy Coalition Submits Petition to FDA for Priority Review of DCCR NDA

PWS Advocacy Coalition Submits Petition to FDA for Priority Review of DCCR NDA

On Friday, August 2, 2024, the PWS Advocacy Coalition submitted a petition to the U.S. Food and Drug Administration (FDA), requesting the filing and priority review of the New Drug Application (NDA) for Soleno Therapeutics’ drug, DCCR. The petition, signed by 14,271 members of the PWS community, was sent to FDA officials Dr. Tiffany Farchione […]

Scroll to top
19202 19204 19198 19200 19196 19164